Cleo Diagnostics (ASX:COV) said alpha testing for its ovarian cancer pre-surgical triage test kit has been completed, according to a Monday Australian bourse filing.

The testing marks a critical step along its manufacturing pathway towards commercial production, the filing said.

The testing confirmed differentiation of benign versus malignant ovarian disease, consistent with its previously published studies.

The company's shares fell past 1% in recent Monday trade.